secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001564590-22-000431
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics appoints Rogério Vivaldi Coelho, M.D., M.B.A. to board of directors
-----------------------------------------------------------------------------

- Board increased from 6 to 7 members; Vivaldi appointed to Class I director, term expiring at 2022 annual meeting.
- Vivaldi also appointed to Audit Committee; receives annual cash retainer of $40,000 plus $7,500 for committee service.
- Granted option to purchase 25,000 shares vesting over three years in equal annual installments.
- Vivaldi brings over 20 years of rare disease pharma experience, including CEO of Sigilon Therapeutics and prior roles at Bioverativ, Spark, and Genzyme.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000156459022000431/0001564590-22-000431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000156459022000431/crnx-8k_20220103.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer